iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)

Subjects:

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Subjects:

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 1. by Rahsan Erdem (11726357)

Subjects:

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced fecal output in a cecectomized rat model. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 3. by Rahsan Erdem (11726357)

Subjects:

Scatterplot of iOWH032 plasma concentrations versus diarrheal stool output rate. by Rahsan Erdem (11726357)

Subjects:

Reverse cumulative distribution plot for diarrheal stool output rate overall in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Diarrheal disease severity by treatment group for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Exposure to low CO₂ levels decreases ER cholesterol levels. by Nityanand Bolshette (17396845)

“…<b>(B)</b> Bioluminescence recordings from the different conditions as depicted in <b>(A)</b>, the arrow indicates the time CO₂ was shifted from 5% to 1% (mean ± SE, <i>n</i> = 4 biological replicates per condition, AUC for 0 mM 0.34 ± 0.007, 1.59 ± 0.004 (<i>P</i> < 0.0001), 0.5 mM 1.00 ± 0.023, 2.68 ± 0.04 (<i>P</i> < 0.0001), 1 mM 1.66 ± 0.07, 3.34 ± 0.04 (<i>P</i> < 0.0001), 3 mM 2.06 ± 0.02, 2.79 ± 0.07 (<i>P</i> < 0.0001), 5 mM 2.02 ± 0.05, 2.43 ± 0.06 (<i>P</i> < 0.002), 7 mM 1.85 ± 0.01, 1.77 ± 0.02 (<i>P</i> < 0.02) two-sided Student’s <i>t</i> test). …”

Decreased capillary density and cardiac fibrosis in <i>Nkx2.5-Cre/Foxm1^fl/fl</i> heart. by Craig Bolte (299486)

“…Capillary density was decreased in <i>Nkx2.5-Cre/Foxm1^fl/fl</i> hearts at P11 (A–B, I), while coronary vessel formation was not altered (C–D). …”

Six weeks of voluntary wheel running decreases 5-HT_2C mRNA expression in the medial dorsal striatum. by Benjamin N. Greenwood (295216)

SPL treatment decreases diabetes-induced decrement in protein expression of cldn-5 in glomeruli (GL) and cldn-2 and occldn in proximal tubules (PT). by Eduardo Molina-Jijón (4020464)

“…<p>SPL prevents diabetes-induced decrease of cldn-5 protein expression (A and B) in GL, and mRNA (F) and protein expression of cldn-2 (A and C), and protein expression of occldn (A and D) in PT (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s002" target="_blank">S2 Fig</a>). …”

The mitochondrial ROS-counteracting protein PRDX3 is decreased in NRF2i-DMA cells. by Bo-hyun Choi (630240)

DN1 and DN2 cells are preferentially increased by TSLP in FTOC and decreased in TSLPRFTOC by Qi Jiang (33521)

Casein kinase 1.2 depletion decreases ZC3H11 phosphorylation. by Igor Minia (399074)

“…Procyclic cells expressing in situ tagged V5-CK1.2, with a tetracycline-inducible stem-loop RNAi construct, were induced with tetracycline (200g/ml). …”

PF treatment decreases expressions of cytochrome c and Bax, but increases the expressions of Bcl-2. by Ruo-Bing Guo (298949)